Background
Methods
Subjects
DNA extraction
IDE SNP selection and genotyping
Aβ1-42plasma level
Statistical analysis
Results
Insulin degrading enzymepolymorphisms and Alzheimer's disease
AD | Aβ42plasma level [pg/ml] | T2DM | |||||
---|---|---|---|---|---|---|---|
Polymorphism (major/minor allele) | focus | OR (95% CI) | p-value | slope (95% CI) | p-value | OR (95% CI) | p-value |
IDE2 (T/C) | baseline | - | - | 22.36 (8.08 - 36.6) |
0.002
| 0.82 (0.23 - 2.86) | 0.75 |
IDE2 (T/C) | 1st follow-up | 0.66 (0.36 - 1.21) | 0.18 | 21.04 (2.08 - 40) |
0.03
| 0.96 (0.3 - 3.05) | 0.95 |
IDE2 (T/C) | 2nd follow-up | 0.55 (0.32 - 0.95) |
0.03
| 35.26 (12.8 -57.8) |
0.002
| 1.32 (0.41 - 4.24) | 0.64 |
IDE2 (T/C) × examination | longitudinal | 1.13 (0.84 - 1.43) | 0.41 | 8.23 (1.93 -14.5) |
0.01
| 1.27 (0.81 - 1.73) | 0.31 |
IDE7 (A/G) | baseline | 1.74 (0.63 - 4.78) | 0.28 | -5.24 (-16.7 - 6.2) | 0.37 | 2.4 (1.25 - 4.63) |
0.009
|
IDE7 (A/G) | 1st follow-up | 1.26 (0.77 - 2.07) | 0.35 | -5.31 (-21 -10.3) | 0.51 | 2.62 (1.32 - 5.18) |
0.006
|
IDE7 (A/G) | 2nd follow-up | 0.97 (0.62 - 1.52) | 0.89 | -14.27 (-33.7 - 5.2) | 0.15 | 3.47 (1.72 - 6.97) |
0.0005
|
IDE7 (A/G) × examination | longitudinal | 0.86 (0.56 - 1.16) | 0.33 | -3.37 (-8.2 - 1.49) | 0.18 | 1.1 (0.91 - 1.3) | 0.32 |
IDE9 (A/G) | baseline | 1.87 (0.71 - 4.92) | 0.21 | -7.36 (-19.5 - 4.8) | 0.24 | 1.65 (0.72 - 3.79) | 0.24 |
IDE9 (A/G) | 1st follow-up | 1.02 (0.62 - 1.69) | 0.94 | -8.39 (-24.9 - 8.1) | 0.32 | 1.17 (0.46 - 3.0) | 0.75 |
IDE9 (A/G) | 2nd follow-up | 0.99 (0.62 - 1.58) | 0.96 | -11.1 (-31.8 - 9.7) | 0.3 | 1.75 (0.7 - 4.37) | 0.23 |
IDE9 (A/G)× examination | longitudinal | 0.88 (0.57 - 1.19) | 0.42 | -0.85 (-5.5 - 3.83) | 0.72 | 0.98 (0.78- 1.17) | 0.81 |
haplotype | AD | Aβ42plasma level [pg/ml] | T2DM | ||||||
---|---|---|---|---|---|---|---|---|---|
5' IDE2 | IDE9 | '3 IDE7 | focus | OR (95% CI) | p-value | Slope (95% CI) | p-value | OR (95% CI) | p-value |
T | A | A | baseline | 2.01 (0.46 -9.47) | 0.34 | -5.8 (-16.1 - 4.5) | 0.27 | 1.01 (0.63 -1.61) | 0.98 |
T | A | A | 1st follow-up | 1.96 (0.98 - 3.9) | 0.06 | -5.33 (-19.5- 8.86) | 0.46 | 0.83 (0.5 - 1.38) | 0.46 |
T | A | A | 2nd follow-up | 1.51 (0.85 -2.68) | 0.16 | -7.37 (-24.7 -9.95) | 0.41 | 0.92 (0.54 -1.59) | 0.78 |
T | A × examination | A | longitudinal | 0.94 (0.63 -1.41) | 0.77 | -0.05 (-0.18- 0.07) | 0.4 | 0.95 (0.84 -1.07) | 0.41 |
T | G | G | baseline | 2.23 (0.82 -6.1) | 0.12 | -6.98 (-20.4- 6.47) | 0.31 | 3.25 (1.31 -8.04) |
0.01
|
T | G | G | 1st follow-up | 1.03 (0.61 -1.74) | 0.92 | -6.78 (-25.1-11.6) | 0.47 | 2.22 (0.81- 6.05) | 0.12 |
T | G | G | 2nd follow-up | 0.93 (0.56 -1.53) | 0.78 | -12.06 (-35.3-1.17) | 0.31 | 3.28 (1.2 - 8.99) |
0.02
|
T | G × examination | G | longitudinal | 0.82 (0.59 -1.14) | 0.25 | -0.01 (-0.23- 0.21) | 0.92 | 0.99 (0.79 -1.24) | 0.93 |
T | A | G | baseline | 0.91 (0.25 -3.26) | 0.89 | -0.62 (-17.9-16.7) | 0.94 | 6.0 (1.29 -27.7) |
0.02
|
T | A | G | 1st follow-up | 1.22 (0.66 -2.26) | 0.52 | -0.75 (-25.13-23.6) | 0.95 | 13.0 (1.47-129.33) |
0.02
|
T | A | G | 2nd follow-up | 1.02 (0.57-1.83) | 0.94 | -13.76 (-43-15.48) | 0.36 | 8.66 (1.54 -48.77) |
0.01
|
T | A × examination | G | longitudinal | 0,99 (0.69- 1.43) | 0.97 | 0.24 (-0.45- 0.94) | 0.49 | 1.28 (0.64 - 2.6) | 0.49 |
C | A | A | baseline | - | - | 26.36 (10.84-41.88) |
0.001
| 0.34 (0.04 -2.63) | 0.3 |
C | A | A | 1st follow-up | 0.65 (0.34-1.23) | 0.18 | 25.93 (5.21-46.64) |
0.01
| 0.59 (0.12 -2.82) | 0.51 |
C | A | A | 2nd follow-up | 0.5 (0.28- 0.88) |
0.02
| 41.5 (17 - 66) |
0.001
| 0.87 (0.18- 4.14) | 0.86 |
C | A × examination | A | longitudinal | 1.08 (0.81-1.46) | 0.59 | 0.23 (-0.38 -0.86) | 0.45 | 1.26 (0.69 -2.32) | 0.45 |
Insulin degrading enzyme polymorphisms and amyloid β42plasma level
IDE2 genotype | Aβ42plasma level [pg/ml] | |
---|---|---|
slope (95% CI) | p-value | |
all genotypes | 23.7 (20.34 - 27.07) | < 2 ∙ 10 |
only T/T | 21.33 (17.73 - 24.94) | < 2 ∙ 10-16
|
only T/C | 25.84 (16.52 - 35.17) | 5.6 ∙ 10-8
|
only C/C | 43.28 (27.7 - 58.86) | 5.23 ∙ 10-8
|
parameter (baseline/risk) | examination | slope (95% CI) | p-value |
---|---|---|---|
IDE2 (T/C) | baseline | 20.72 (6.23 - 35.21) |
0.005
|
AD (no/yes) | -7.45 (-50.34 - 35.45) | 0.73 | |
IDE2 × AD | - | - | |
IDE2 (T/C) | 1st follow-up | 13.60 (-6.92 - 34.11) | 0.19 |
AD (no/yes) | 7.36 (-23.75 - 38.48) | 0.64 | |
IDE2 × AD | 33.91 (-22.02 - 89.84) | 0.24 | |
IDE2 (T/C) | 2nd follow-up | 21.41 (-3.43 - 46.25) | 0.09 |
AD (no/yes) | 36.27 (3.72 - 68.82) |
0.03
| |
IDE2 × AD | 76.89 (24.01 - 129.77) |
0.005
|